Tegsedi’s Therapeutic Benefits Sustained Over 3 Years in Study
Treatment with Tegsedi (inotersen) for more than three years continued to slow disease progression and improve the quality of life in people with familial amyloid polyneuropathy (FAP), according to new data from the extension study of the NEURO-TTR trial. Patients who started treatment earlier experienced greater benefits, but…